Conatus Announces Proposed Public Offering of Common Stock

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Conatus Announces Proposed Public Offering of Common Stock

SAN DIEGO, April 1, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT ), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Conatus also expects to grant to the underwriters for the offering a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Conatus. Conatus intends to use the net proceeds from the offering to fund clinical development of emricasan, including preparation for registration trials, and for working capital and other general corporate purposes.

Stifel and Roth Capital Partners are acting as book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The securities described above are being offered by Conatus pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com , or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660 or by telephone at (800) 678-9147. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov .

About Conatus Pharmaceuticals

Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding Conatus' expectations on the completion, timing and size of the proposed public offering and the anticipated use of proceeds therefrom. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Conatus' business, including those described in the company's periodic filings with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

MEDIA: David Schull Russo Partners, LLC (858) 717-2310 INVESTORS: Alan Engbring Conatus Pharmaceuticals Inc. (858) 376-2637

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 56

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 158

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 114

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 82

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices

Updated Category News Views 47

Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 117

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 220

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes

Updated Category News Views 22

A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 177

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading

Top 5 Most Recently Viewed Articles

Impact of Withdrawal on Menthol Cigarette Regulation Efforts

Updated Category News Views 158

The Trump Administration's Recent Decision Recently, the Trump administration made headlines by withdrawing a previously proposed ban on menthol cigarettes in the United States. This decision marks a significant setback for health regulators and activists who have long been advocating for healthier tobacco policies. Background of the Proposal In April 2022, the Food and...

Continue Reading
Carta Healthcare Secures Gold by Innovating Clinical Data

Updated Category News Views 18

Tackling a Stubborn Healthcare Pain Point Let's face it: the healthcare industry's data management game has been sweating buckets over a Herculean task for years. A staggering $10-15 billion gets burned annually thanks to inefficient clinical data abstraction. Today's hero of this tale? Carta Healthcare, which just snagged a shining Gold at the 2026 Stevie Awards in...

Continue Reading
SentinelOne Earns Prestigious Recognition from Gartner for 2024

Updated Category News Views 456

SentinelOne's Recent Achievement in Cloud Security SentinelOne (NYSE: S), a prominent player in the field of AI-driven security solutions, has recently been acknowledged as a Customers' Choice in the 2024 Gartner® Peer Insights™ report specifically for Cloud-Native Application Protection Platforms. This recognition reflects feedback from a broad user base, emphasizing...

Continue Reading
Tingus Goose: A Premium Idle Game Experience on Steam

Updated Category News Views 201

Exciting Announcement for Gamers The cult phenomenon, Tingus Goose, is making its debut on Steam as a fully enhanced 1.0 edition designed for PC players. Co-published by Playsaurus and Ultraplayers, this adaptation aims to deliver the ultimate idle gaming experience, free from the distractions found in mobile versions. What’s New in Tingus Goose? Unique Gameplay...

Continue Reading
TrackerRMS Launches Innovative Onboarding+ Solution for Staffing

Updated Category News Views 368

Introducing the New Onboarding+ Solution by TrackerRMS TrackerRMS has taken a significant step in revolutionizing the recruitment landscape with the introduction of its Onboarding+ solution. This innovative tool is designed specifically for recruitment agencies looking to enhance their onboarding process and improve the overall candidate journey. By integrating advanced...

Continue Reading